Time filter

Source Type

Kakadiya J.,Jodhpur National University | Shah N.,Dharmaj Degree Pharmacy College
Journal of Applied Pharmaceutical Science | Year: 2011

Present study was designed to evaluate in Renoprotective activity of Pioglitazone and Glimepiride on Ischemia/reperfusion (I/R) induced renal damage in diabetic rats. Ischemia/reperfusion injury, which is commonly seen in the field of renal surgery or transplantation in diabetic condition, is a major cause of acute renal failure. Type 2 Diabetes was induced in rats by a single intraperitoneal (i.p) injection of Streptozotocin (65 mg/kg, STZ) in overnight fasting rats followed by the i.p administration of Nicotinamide (110 mg/kg, NIC) after 15 minutes. After right nephrectomy, Piogltazone (10 mg/kg/day, p.o) and Glimepiride (0.5 mg/kg/day, p.o) were administered for 15 days. On the 16th day, ischemia was induced in contra lateral kidney for 45 min, followed by reperfusion for 24 hr. renal function marker and oxidative parameter were estimated at the end of 24 hr reperfusion. At the end of experimental period the level of malondialdehyde formation/ lipid peroxidation (LPO) in kidney tissue and serum marker Creatinine, Urea and Uric acids were significantly increased. Whereas, the activity of biomarkers of oxidative stress such as reduced glutathione (GSH), Catalase (CAT) and superoxide dismutase (SOD) were found to be decreased significantly compared to control rats. Pioglitazone improved the renal dysfunction and oxidative stress after renal ischemia/reperfusion injury in diabetic rats, but Glimepiride less improved the renal marker change compared to treatment of Pioglitazone. In conclusion, Pioglitazone shows potent may improve renal function marker and oxidative stress in kidney in I/R induced renal damage in type 2 diabetic rats.


Mulani H.T.,Jodhpur National University | Patel B.,Dharmaj Degree Pharmacy College | Shah N.J.,Dharmaj Degree Pharmacy College
Journal of Applied Pharmaceutical Science | Year: 2011

The characteristics of a new Polyvinylacetate/Povidone based excipient, Kollidon® SR were evaluated for application in extended release matrix tablets. The effects of the following formulation and process variables on tablet properties and drug release were tested: Kollidon® SR concentration in the tablet, addition of external binder for wet granulation, presence of an enteric polymer in the matrix, method of manufacturing and compression force. The similarities in release profiles were evaluated by applying the model independent f2 similarity factor. It was found that Kollidon® SR is suitable for pH-independent extended release matrix tablets. A minimum concentration of 30% polymer was necessary to achieve a coherent matrix, able to extend the release of the incorporated drugs. Increasing the Kollidon® SR concentration in the tablet led to a slower drug release. Drug release followed square root of time dependent kinetics, thus indicating a diffusion-controlled release mechanism. The drug release was influenced by the aqueous solubility of the drug. The drug release rate was faster for wet granulation than direct compression, thus making direct compression the method of choice for manufacturing Kollidon® SR extended release systems. It was found that Kollidon® SR was the main release controlling agent in the presence of an external binder or enteric polymer in the matrix. A significant reduction in the dissolution rates associated with an increase in tablet hardness was observed during the stability test under accelerated conditions. The developed propranolol matrix tablets formulation was compared to the reference listed product (Inderal® LA capsules). It was concluded that Kollidon® SR is a potentially useful excipient for the production of pH-independent extended release matrix tablets.


Kakadiya J.,Dharmaj Degree Pharmacy College | Shah N.J.,Dharmaj Degree Pharmacy College
Research Journal of Pharmaceutical, Biological and Chemical Sciences | Year: 2010

Present study was designed to evaluate in vitro antioxidant activity in heart of Pioglitazone on isoproterenol induced myocardial infarction in normal and diabetic in rats. Pioglitazone (10mg/kg, p.o) was administered for 28 days in rats injected with single dose of Streptozotocin (65 mg/kg, i.p, STZ) and nicotinamide (110 mg/kg, i.p, NIC) and after isoproterenol (200mg/kg, s.c., ISO) induced myocardial infarction in diabetic rats on 29th and 30th day. At the end of experimental period (i.e. on the day 31) heart tissue sample of each rat was collected and antioxidative parameter carried out for further estimations. Administration of STZ-NIC in rats showed a significant (p<0.001) increased in the levels of serum glucose, glycosylated heamoglobin (HbA1c). At the end of experimental period the level of malondialdehyde formation/lipid peroxidation (LPO) in liver tissue was significantly increased. Whereas, the activity of biomarkers of oxidative stress such as reduced glutathione (GSH), catalase (CAT) and superoxide dismutase (SOD) were found to be decreased significantly compared to control rats. Treatment with Pioglitazone significantly restored GSH level, SOD as well as catalase activity and reduced lipid peroxidation in compared to diabetic control group. This study concluded that PIO at 10 mg/kg may show reduced oxidative stress in heart on isoproterenol induced myocardial infarction in type 2 diabetic rats.


Kakadiya J.,Dharmaj Degree Pharmacy College | Shah N.J.,Dharmaj Degree Pharmacy College
Research Journal of Pharmaceutical, Biological and Chemical Sciences | Year: 2010

Present study was designed to evaluate Valsartan on isoproterenol induced myocardial infarction and histopathological in normal and Streptozotocin-Nicotinamide induced diabetic in rats. Valsartan (8 mg/kg, p.o) was administered for 28 days in rats injected with single dose of Streptozotocin (65 mg/kg, i.p, STZ) and Nicotinamide (110 mg/kg, i.p, NIC) and after isoproterenol (200mg/kg, s.c, ISO) induced myocardial infarction in rats on 29th and 30th day. At the end of experimental period (i.e. on the day 31) blood samples were collected and animals were euthanized. A heart tissue sample of each rat was collected and glycogen and nitrite carried out for further estimations. Administration of STZ-NIC in rats showed a significant (p<0.001) increased in the levels of serum glucose, glycosylated heamoglobin (HbA1c), creatine kinase (CK), Glutamate oxaloacetate transferase (GOT), glycogen and nitrite whereas the levels of myocardial infarct size was found low to be significant (p<0.05). Treatment with Valsartan no significantly change HbA1c, glucose level and glycogen but significantly reduced CK (P<0.05), GOT (P<0.01) and nitrite (P<0.01) in compared to diabetic control group. The myocardial infarction in diabetic rats also led to severe splaying of muscle fiber, heavy neutrophil infiltration and cellular edema than non diabetic rats. The VAL treated diabetic rats exhibited reduction in necrosis with less fragmentation of fibres as compared to diabetic control groups, which reflects the cardio protective effect of VAL This study concluded that VAL at 8 mg/kg may show reduce experimentally induced myocardial infarction in type 2 diabetic rats.


Kakadiya J.,Dharmaj Degree Pharmacy College | Shah M.,Dharmaj Degree Pharmacy College | Shah N.J.,Dharmaj Degree Pharmacy College
Research Journal of Pharmaceutical, Biological and Chemical Sciences | Year: 2010

Present study was designed to evaluate effect of Nobivolol on serum glucose, HbA1c and lipid profile in normal and Streptozotocin-Nicotinamide induced diabetic in rats. Nobivolol (2 mg/kg, p.o) was administered for 28 days in rats injected with single dose of Streptozotocin (65 mg/kg, i.p, STZ) and Nicotinamide (110 mg/kg, i.p, NIC). Administration of STZ-NIC in rats showed a significant (p<0.001) increased in the levels of serum glucose, glycosylated heamoglobin (HbA1c), Total Cholesterol (TC), Triglycerides (TG) and High density lipoprotein (HDL) whereas the levels of Low density lipoprotein (LDL)) were found to be non significant. Treatment with Nobivolol significantly (P<0.001) decreased LDL and (P<0.01) decreased TC and TG level but no significantly change HbA1c, glucose level and HDL in compared to diabetic control group. We concluded that NOB (2 mg/kg, p.o) was improves lipid profile in diabetic rats without any effective in blood glucose and HbA1c levels.


Kakadiya J.,Dharmaj Degree Pharmacy College | Mulani H.,Dharmaj Degree Pharmacy College | Shah N.,Dharmaj Degree Pharmacy College
International Journal of Advances in Pharmaceutical Sciences | Year: 2010

Present study was designed to evaluate effect Glimepiride on Glucose, HbA1c, lipid profile and Lipid Metabolizing Enzymes in isoproterenol induced myocardial infarction in normal and Streptozotocin-Nicotinamide induced in diabetic rats. Glimepiride (0.5 mg/kg, p.o) was administered for 28 days in rats injected with single dose of Streptozotocin (65 mg/kg, i.p, STZ) and Nicotinamide (110 mg/kg, i.p, NIC) and after isoproterenol (200 mg/kg, s.c.) induced myocardial infarction in rats on 29th and 30th day. At the end of experimental period (i.e. on the day 31) serum and heart tissues sample were collected, and glucose, HbA1c and Total Cholesterol (TC), Triglycerides (TG) and High density lipoprotein (HDL) and cholesterol ester synthetase (CES), lecithin Cholesterol acyl transferase (LCAT), lipoprotein lipase (LPL) were find out. Administration of STZ-NIC in rats showed a significant (p<0.001) increased in the levels of serum glucose, glycosylated heamoglobin (HbA1c), Total Cholesterol (TC), Triglycerides (TG) and Low density lipoprotein (LDL) whereas the levels of High density lipoprotein (HDL) were found to be non significant but significant (p<0.001) increased in the level of heart tissues CES and significant (p<0.001, p<0.01) decreased LCAT and LPL as compared to respective control groups. Treatment with Glimepiride significantly (P<0.001) decreased HbA1c, glucose, CES level and significantly (P<0.001, P<0.05, P<0.05) decreased LDL, TC and TG and significant (P<0.01) increased LCAT and LPL level but no significantly change HDL in compared to diabetic control group. This study suggested that GLI (0.5 mg/kg) is effective in controlling blood glucose levels and improves lipid profile and lipid metabolizing enzymes in experimentally induced myocardial infarction diabetic rats. © arjournals.org.

Loading Dharmaj Degree Pharmacy College collaborators
Loading Dharmaj Degree Pharmacy College collaborators